All In Biotech

NDA 018304 · Fresenius Kabi USA

Sensorcaine

Bupivacaine Hydrochloride, Epinephrine Bitartrate · Injection

Last checked: Nov 20, 2026Latest source record: Jul 19, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1981

Dec 30, 1981

Approved uses

1

Original approval plus efficacy supplements

Registered trials

2,836

341 Phase 3, 228 recruiting

FAERS reports

2,545

1,664 serious, 231 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 9, 2026.

INDICATIONS & USAGE Sensorcaine (bupivacaine HCl) is indicated for the production of local or regional anesthesia or analgesia for surgery, dental and oral surgery procedures, diagnostic and therapeutic procedures, and for obstetrical procedures. Only the 0.25% and 0.5% concentrations are indicated for obstetrical anesthesia (see WARNINGS). Experience with nonobstetrical surgical procedures in pregnant patients is not sufficient to recommend use of the 0.75% concentration of bupivacaine HCl in these patients. Sensorcaine is not recommended for intravenous regional anesthesia (Bier Block) (see WARNINGS). The routes of administration and indicated Sensorcaine concentrations are: Standard textbooks should be consulted to determine the accepted procedures and techniques for the administration of Sensorcaine. Table1.jpg

Therapeutic areas: Kidney and urology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 30, 1981 Original approval
5 products under this application
  • SENSORCAINE · BUPIVACAINE HYDROCHLORIDE 0.75%; EPINEPHRINE BITARTRATE 0.0091MG/ML · INJECTABLE, INJECTION · Prescription · TE AP
  • SENSORCAINE · BUPIVACAINE HYDROCHLORIDE 0.75% · INJECTABLE, INJECTION · Prescription · TE AP
  • SENSORCAINE · BUPIVACAINE HYDROCHLORIDE 0.25% · INJECTABLE, INJECTION · Prescription · TE AP
  • SENSORCAINE · BUPIVACAINE HYDROCHLORIDE 0.5%; EPINEPHRINE BITARTRATE 0.0091MG/ML · INJECTABLE, INJECTION · Prescription · TE AP
  • SENSORCAINE · BUPIVACAINE HYDROCHLORIDE 0.5% · INJECTABLE, INJECTION · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Bupivacaine" as an intervention, any sponsor and status, largest first.

All 2,836 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective653
  • anaesthetic complication215
  • musculoskeletal pain202
  • maternal exposure during pregnancy196
  • off label use180
  • hypoaesthesia152
  • hypotension128
  • condition aggravated126
  • joint injury126
  • dyspnoea122
  • hypertension118
  • headache114

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200420
200510
200630
200714
200828
2009158
201078
201139
201237
201337
201428
2015106
2016283
201735
201878
201988
2020107
2021138
2022255
2023188
2024275
2025302
2026211

Recalls

1 FDA enforcement reports for this application.

  • Dec 10, 2020 · Class II · Terminated

    Subpotent Drug: Low out-of-specification assay results for the epinephrine component.

Shortages

FDA's drug shortage list.

  • Current · updated Nov 18, 2026

    Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-462-31). Delay in shipping of the drug

  • Current · updated Nov 18, 2026

    Sensorcaine, Injection, 5 mg/1 mL (NDC 63323-466-17). Check wholesalers for inventory

  • Current · updated Nov 18, 2026

    Sensorcaine, Injection, 2.5 mg/1 mL (NDC 63323-465-57). Check wholesalers for inventory

  • Current · updated Nov 18, 2026

    Sensorcaine, Injection, 2.5 mg/1 mL (NDC 63323-464-31). Demand increase for the drug

  • Current · updated Nov 18, 2026

    Sensorcaine, Injection, 5 mg/1 mL (NDC 63323-466-31). Delay in shipping of the drug

  • Current · updated Nov 3, 2026

    Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-462-37). Other

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Sensorcaine (Bupivacaine HCl)

2024 spending

$185

Beneficiaries

n/a

11 claims

Per beneficiary

n/a

$0.19 per unit

View as table
YearSpending
2020$357
2021$462
2022$141
2023$369
2024$185

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 5,897 on PubMed

Sponsor: Fresenius Kabi USA

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.